Skip to content
ClinCalc Pro
Menu
infectious-disease

HIV CD4/Viral Load Monitoring Intervals

Evidence-based guide to CD4 count and viral load monitoring frequency in people living with HIV (PLHIV) on antiretroviral therapy (ART). Based on BHIVA HIV monitoring guidelines 2023. Helps determine appropriate review intervals.

Score interpretation

ART-Naive / Early ART 0

Pre-treatment or early ART: frequent monitoring required

→ Baseline: CD4, VL, FBC, U&E, LFT, glucose, lipids, HLA-B*57:01, resistance genotype, Hep B/C, syphilis, STI screen, TB screen; CD4 + VL at 1 and 3 months after ART start; VL target <50 copies at 6 months; continue 3-monthly until VL stable; cervical smear (women); review adherence at every visit

Virologically Stable — Standard Monitoring 1

On ART with VL <50 for >12 months — reduced monitoring acceptable

→ Annual CD4 count (can omit if CD4 >500 for >2 years and VL consistently <50); viral load every 6 months (or annually if very stable per clinician judgement); annual lipids, glucose, renal, LFT; STI screen annually (or per risk); annual blood pressure, weight, cardiovascular risk; flu vaccine annually; 3-yearly smear; ophthalmology if CD4 ever <100

Virological Failure — Urgent Review 2–3

VL >200 or low-level viraemia — virological failure or blip

→ Repeat VL in 4 weeks; assess adherence thoroughly; resistance genotype testing if confirmed VL >500; review drug interactions; HIV specialist review; consider ART switch if resistance confirmed; target VL <50 copies within 3–6 months of regimen change; psychosocial adherence support; review for intercurrent illness; CD4 every 3 months until stable

Interpretation bands for the HIV CD4 Monitoring. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.